The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells

Abstract

BackgroundHepatocellular carcinoma (HCC) is one of the major causes of mortality. ABT-263 is a newly synthesized, orally available Bcl-2/xL inhibitor that shows promising efficacy in HCC therapy. ABT-263 inhibits the anti-apoptotic activity of Bcl-2 and Bcl-xL, but not Mcl-1. Previous reports have shown that ABT-263 upregulates Mcl-1 in various cancer cells, which contributes to ABT-263 resistance in cancer therapy. However, the associated mechanisms are not well known.MethodsWestern blot, RNAi and CCK-8 assays were used to investigate the relationship between Mcl-1 upregulation and ABT-263 sensitivity in HCC cells. Real-time PCR and Western blot were used to detect Mcl-1 mRNA and protein levels. Luciferase reporter assay and RNA synthesis inhibition assay were adopted to analyze the mechanism of Mcl-1 mRNA upregulation. Western blot and the inhibition assays for protein synthesis and proteasome were used to explore the mechanisms of ABT-263-enhanced Mcl-1 protein stability. Trypan blue exclusion assay and flow cytometry were used to examine cell death and apoptosis.ResultsABT-263 upregulated Mcl-1 mRNA and protein levels in HCC cells, which contributes to ABT-263 resistance. ABT-263 increased the mRNA level of Mcl-1 in HCC cells by enhancing the mRNA stability without influencing its transcription. Furthermore, ABT-263 increased the protein stability of Mcl-1 through promoting ERK- and JNK-induced phosphorylation of Mcl-1Thr163 and increasing the Akt-mediated inactivation of GSK-3β. Additionally, the inhibitors of ERK, JNK or Akt sensitized ABT-263-induced apoptosis in HCC cells.ConclusionsABT-263 increases Mcl-1 stability at both mRNA and protein levels in HCC cells. Inhibition of ERK, JNK or Akt activity sensitizes ABT-263-induced apoptosis. This study may provide novel insights into the Bcl-2-targeted cancer therapeutics.

S6K1 inhibition enhances the apoptotic cell death of breast cancer cells in response to Bcl-2/Bcl-xL inhibition by the downregulation of survivin

“…ABT263 is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins that binds with high affinity to Bcl-2 and Bcl-xL, and antagonizes their anti-apoptotic function (20). In the present study, ABT263 (≤2 µM) treatment resulted in upregulated Mcl-1 expression, in agreement with a previous report (21). However, ABT263 (≤2 µM) did not induce apoptotic cell death in BT474 breast cancer cells (Fig.…”

Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells

“…ERK activation inhibits the processing of caspase-8 and Bid, thereby turning off the mitochondrial amplification loop [26,27]. Previous studies showed that Mcl-1 protein expression is enhanced due to ERK activation [28][29][30]. In our study, we observed that activation of ERK and protein level of MCL-1 decreased in Msi1 knockdown LH86-TR cells whereas increased in Msi1 overexpressing LH86 cells.…”

Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy

“…Additionally, the human hepatocellular carcinoma cancer often overexpresses Mcl-1, probably because of the various apoptosis inducing factors such as hypoxia, pH imbalances, and altered metabolism in which tumors reside, but also because of the benefits of Mcl-1 protein for cytoprotection [20,21].…”